SEC Comment Letter 0000000000-24-006090 to Cuprina Holdings (Cayman) LTD (CUPR)
Cuprina Holdings (Cayman) LTD
Date: May 24, 2024 · CIK: 0001995704 · Accession: 0000000000-24-006090
AI Filing Summary & Sentiment
File numbers found in text: 333-277731
Show Raw Text
United States securities and exchange commission logo
May 24, 2024
David Quek Yong Qi
Chief Executive Officer
Cuprina Holdings (Cayman) Limited
Blk 1090 Lower Delta Road #06-08
Singapore 169201
Re:Cuprina Holdings (Cayman) Limited
Amendment No. 1 to Registration Statement on Form F-1
Filed May 16, 2024
File No. 333-277731
Dear David Quek Yong Qi:
We have reviewed your amended registration statement and have the following
comments.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe a comment applies to your facts and circumstances
or do not believe an amendment is appropriate, please tell us why in your response.
After reviewing any amendment to your registration statement and the information you
provide in response to this letter, we may have additional comments.
Amendment No. 1 to Registration Statement on Form F-1
Underwriting
Lock-up Agreements, page 162
1.Please revise to specify the exceptions to the lock-up agreements.
General
2.Please revise the cover pages of both the primary and resale prospectuses to clearly state,
if true, that the selling shareholders may not commence their resale of shares until after
the IPO closes. Please also revise to clarify, if true, that neither the primary offering nor
the resale offering will proceed if your ordinary shares are not approved for listing on
Nasdaq.
3.We refer to your explanatory note regarding the two prospectuses for the primary and
secondary offering as well as your registration statement cover page which appears to
FirstName LastNameDavid Quek Yong Qi
Comapany NameCuprina Holdings (Cayman) Limited
May 24, 2024 Page 2
FirstName LastName
David Quek Yong Qi
Cuprina Holdings (Cayman) Limited
May 24, 2024
Page 2
indicate that the resale offering will be made pursuant to Rule 415. Please provide us an
analysis explaining your basis for determining that the secondary offering is eligible to be
made under Rule 415(a)(1)(i). In responding, please consider the guidance provided in
Compliance Disclosure Interpretations, Securities Act Rules, Question 612.09. In your
response, please tell us whether either of the selling shareholders have business or familial
relationships with employees or affiliates of your company.
4.We note your disclosure on your resale prospectus cover page and page ALT-2 that your
selling shareholders may sell their securities through one or more transactions that may
take place in ordinary brokers’ transactions, privately negotiated transactions or through
sales to one or more dealers for resale of such securities as principals. Please confirm your
understanding that the retention by a selling shareholder of a dealer or underwriter would
constitute a material change to your plan of distribution requiring a post-effective
amendment. Please also revise Item 9 to provide the undertakings required by Item 512(a)
of Regulation S-K.
5.Please revise the cover page of the resale prospectus so that it does not assume the prior
consummation of your primary initial public offering and listing of your Class A ordinary
shares on Nasdaq.
Please contact Christine Torney at 202-551-3652 or Angela Connell at 202-551-3426 if
you have questions regarding comments on the financial statements and related matters. Please
contact Doris Stacey Gama at 202-551-3188 or Alan Campbell at 202-551-4224 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Mathew Lewis, Esq.